Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Collaborators: Nathan Kline Institute for Psychiatric Research; National Institute of Mental Health (NIMH); Sarah Herzog Hospital; The Zucker Hillside Hospital; University of California, Los Angeles; University of Maryland, College Park
• Treatments: Cycloserine; Glycine

Criteria

Inclusion Criteria:

• diagnosis of schizophrenia or schizoaffective disorder

• stable, enduring negative symptoms above a certain level (SANS >19)

• clinically stable, with psychotic symptoms measured on BPRS below 19, anxiety/depression on BPRS below 15

• extrapyramidal symptoms measured on SAS below 9

• on stable antipsychotic regimen (not including clozapine)

Exclusion Criteria:

• alcohol or substance dependence within last six months

• alcohol or substance abuse within last month

• organic brain disorder

• medical condition whose pathology or treatment could alter the presentation or treatment of schizophrenia, including active tuberculosis or tuberculosis treatment, kidney stones, and uncontrolled diabetes mellitus

• Female participants could not be pregnant and were required to be using a documented method of contraception.